GENMAB A/S

Based in Copenhagen, Denmark, Genmab A/S is a biotechnology company that develops and commercializes antibody-based therapeutics primarily for oncology and other disease areas. The company markets several approved products across hematologic and solid malignancies, including EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, Tivdak for recurrent cervical cancer, and RYBREVANT for non-small cell lung cancer. Beyond oncology, Genmab also markets DARZALEX/DARZALEX FASPRO for multiple myeloma, Kesimpta for relapsing multiple sclerosis, and TEPEZZA for thyroid eye disease.

The company maintains a substantial pipeline of candidates in development across multiple therapeutic areas, including continuation of its lead oncology programs alongside earlier-stage assets targeting solid tumors and rare diseases such as hemophilia A, sickle cell disease, and multiple system atrophy. Genmab operates through numerous collaboration agreements with major pharmaceutical and biotechnology partners including AbbVie, Pfizer, BioNTech, Johnson & Johnson, Bristol Myers Squibb, and Amgen, which support development and commercialization of various programs.

With approximately 2,973 full-time employees, Genmab operates as a publicly listed company on Nasdaq. The company's commercial reach extends across markets with approved products generating revenue from both oncology and specialty therapeutics segments.